<DOC>
	<DOCNO>NCT01751802</DOCNO>
	<brief_summary>The purpose research study gather scientific information effectiveness safety study drug , Ecopipam ( PSYRX 101 ) , treatment self-injurious behavior compare effectiveness safety placebo ( inactive substance ) subject Lesch-Nyhan Disease .</brief_summary>
	<brief_title>Ecopipam Treatment Self-Injurious Behavior Subjects With Lesch-Nyhan Disease</brief_title>
	<detailed_description>This study do approximately 6 center approximately 4 country , approximately 24 subject include . This study divide two part . The first double-blinded portion last 18 week total . The second portion optional open-label extension last 54 week total . The total duration study , choose participate portion , anticipate approximately 78 week . The first portion study double-blind assignment treatment group do randomly . In study , two treatment group . One group receive Ecopipam one 6-week period placebo two 6-week period , group receive Ecopipam two 6-week period placebo one 6-week period . Subjects experience clinically significant side effect blind portion study may eligible participate open-label extension may last 54 week .</detailed_description>
	<mesh_term>Self-Injurious Behavior</mesh_term>
	<mesh_term>Lesch-Nyhan Syndrome</mesh_term>
	<mesh_term>Ecopipam</mesh_term>
	<criteria>Subjects must classic LND defined ( ) characteristic clinical syndrome ( evidence overproduction uric acid , severe generalize dystonia , frequent persistent selfinjurious behavior ( SIB ) , cognitive impairment ) ( b ) laboratory confirmation mutation HPRT gene severe deficiency associate enzyme . Subjects must minimum combined score 20 Behavior Problems Inventory ( BPI ) SIB subscales frequency severity assess caregiver . Subjects must minimum score 4 Physician 's Global Impression ( PGI ) severity scale . Subject must â‰¥ 6 year old . Subjects must weigh &gt; 10 kg . Subjects currently treat medication seizure . Subjects neuroleptic dopaminedepleting agent . Subjects impaired renal function define serum creatinine &gt; 1.5 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lesch Nyhan Disease</keyword>
	<keyword>Self-Injury</keyword>
</DOC>